Cardiff Oncology Inc
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
CRDF$0.80+5.3%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Comprehensive Loss
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Net loss | $(41,441) | $(38,704) |
| Other comprehensive loss: | ||
| Unrealized gain (loss) on securities available-for-sale | 328 | (253) |
| Total comprehensive loss | $(41,113) | $(38,957) |
| Preferred stock dividend payable on Series A Convertible Preferred Stock | (24) | (24) |
| Comprehensive loss attributable to common stockholders | $(41,137) | $(38,981) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.